Abbott Laboratories (ABT) EV to EBITDA (2009 - 2026)

Abbott Laboratories has disclosed EV to EBITDA across 18 years of filings, most recently posting 89.82 for Q2 2026.

• In Q2 2026, EV to EBITDA fell 19.76% year-over-year to 89.82; the TTM figure through Jun 2026 stood at 20.7 (down 32.28% YoY), while the FY2025 annual figure was 26.0, down 5.81% from the prior year.
• EV to EBITDA came in at 89.82 for Q2 2026 at Abbott Laboratories, down from 128.01 in the prior quarter.
• In the past five years, EV to EBITDA ranged from a high of 138.69 in Q4 2022 to a low of 68.45 in Q1 2022.
• Average EV to EBITDA over 5 years is 106.14, with a median of 103.74 recorded in 2024.
• Year-over-year, EV to EBITDA sank 46.06% in 2022 and jumped 61.47% in 2023.
• Over 5 years, EV to EBITDA stood at 138.69 in 2022, then slipped by 25.49% to 103.34 in 2023, then decreased by 4.57% to 98.61 in 2024, then dropped by 5.65% to 93.03 in 2025, then fell by 3.45% to 89.82 in 2026.
• Per Business Quant data, the three most recent EV to EBITDA figures were 89.82 in Q2 2026, 128.01 in Q1 2026, and 93.03 in Q4 2025.